Source: Eur Respir J, 51 (4) 1702258; 10.1183/13993003.02258-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Angelo M. Taveira-DaSilva, Patricia Julien-Williams, Amanda M. Jones, Mario Stylianou, Joel Moss. Rates of change in FEV₁ and D_LCO as potential indicators for mTOR inhibitor therapy in premenopausal lymphangioleiomyomatosis patients. Eur Respir J, 51 (4) 1702258; 10.1183/13993003.02258-2017

Member's Comments

No comment yet.

Related content which might interest you: FVC decline in patients with SSc-ILD by use of anti-acid therapy Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids? Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Is radiologic evidence of interstitial infiltrate enough to predict FEV1 and DLCO disparity in lung cancer patients? Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV1 =80% predicted Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients Source: Virtual Congress 2021 – Treatments for airway diseases Year: 2021 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 The evaluation of different factors that cause FEV1 decline in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 135s Year: 2001 Implications of DLCO corrected by hemoglobin concentration for lung function preoperator risk evaluation in obese and non obese stable COPD patients Source: Annual Congress 2007 - Quality, sleep and exercise - the ingredients for a perfect life! Year: 2007 Closing volume predicts the FEV1 response to bronchodilators in patients with COPD Source: Virtual Congress 2020 – Advances in lung function testing Year: 2020 Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Rate of FEV1 decline by FEV1 percent predicted in UPLIFT® and TIOSPIR® Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Improved survival with increased IC/TLC ratio, DLCO and FEV1 in an analysis of a COPD pulmonary function database Source: Annual Congress 2011 - Lung and airway function Year: 2011 FVC decline over 1 year predicts mortality but not subsequent FVC decline in patients with IPF Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Does an acute FEV1 response predict long-term improvements with bronchodilators in patients with COPD? Source: Eur Respir J 2001; 18: Suppl. 33, 486s Year: 2001 Biomarkers to predict FEV1 decline in smokers and early-onset COPD. Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 Does the decrease in KCO go typically with DLCO decrease in obstructive pulmonary diseases? The relationship with DLCO, KCO, VA and VA/TLC in patients with COPD> Source: International Congress 2018 – Functional assessment of COPD Year: 2018 Association between weight loss and decline in FVC in patients with IPF Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Comparison of spirometric z-scores with FEV1 percent prediction in predicting exacerbations in elderly COPD patients Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Osteoprotogerin plasma concentrations is correlate with forced expiratory volume at 1 second (FEV1) in patients with COPD Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013